Resources for your Patient


IC-ONC Patient Resources and Tools on Immunotherapy and Immune-Related Adverse Events

Program Overview

This patient-centric activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.

Target Audience

This initiative is designed for patients with cancer who are treated or eligible for treatment with immunotherapy.

Co-provided by Ultimate Medical Academy/Complete Conference Management
This activity is supported by an educational grant from Merck & Co., Inc

Full details view activity

Non-Small-Cell Lung Cancer - Augmented Reality

Description:

Non-small-cell lung cancer (NSCLC) is 1 of 2 main types of lung cancer. It develops from epithelial cells that line the lung airways and sacs, some of which produce mucus that lubricates and protects the lung. Cancer cells use a variety of ways to avoid the body’s natural defense—the immune system—to continue to grow, invade, and spread. In various types of NSCLC, molecular interactions between PD-1 on our immune system’s T-cells and PD-L1 on cancer cells drive whether or not the body’s immune system will attack a cancer cell. This program will look at the cellular underpinnings of NSCLC, as well as agents—known as checkpoint inhibitors—that target PD-1 or PD-L1 for improved management of this condition.

Medical Management of Melanoma - Augmented Reality

Description:

Melanoma is a type of skin cancer in which melanocytes— the cells that give skin its tan or brown color—start to grow out of control. While less common than some other types of skin cancer, melanoma is more likely to grow and spread. Cancer cells use a variety of ways to avoid the body’s natural defense—the immune system—to continue to grow, invade, and spread. In melanoma, molecular interactions between PD-1 on our immune system’s T-cells and PD-L1 on cancer cells drive whether or not the body’s immune system will attack a cancer cell. This program will look at the cellular underpinnings of melanoma, as well as agents—known as checkpoint inhibitors—that target PD-1 or PD-L1 for improved management of this condition.

Squamous Cell Cancer-Head/Neck

Description:

Squamous cell carcinomas of the head and neck (SCCHN) are a group of cancers that develop from a thin, moist layer of squamous cells—called a mucosal surface—that line the inner structures of the head and neck, such as the mouth, nose, and throat. Cancer cells use a variety of ways to avoid the body’s natural defense—the immune system—to continue to grow, invade, and spread. In SCCHN, molecular interactions between PD-1 on our immune system’s T-cells and PD-L1 on cancer cells drive whether or not the body’s immune system will attack a cancer cell. This program will look at the cellular underpinnings of SCCHN, as well as agents—known as checkpoint inhibitors—that target PD-1 or PD-L1 for improved management of this condition.

Make your own Immuno-Oncology poster

Make Your Own Immunooncology: Biomarkers & irAEs Poster